You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
SBC: ADVANTAGENE, INC Topic: N/ADESCRIPTION (provided by applicant): The main objective of this project is to develop a new therapeutic to improve the outcome for patients with intermediate-risk prostate cancer. The indication is a first-line adjuvant to be combined with radiation therapy for prostate cancer. The desired outcomes are improved local control rate, decreased recurrence and improved disease-free survival. This grant ...
SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health -
A Clinical Trial of Antimicrobial Skin Substitutes for Treatment of Diabetic Ulce
SBC: Stratatech Corporation Topic: NIDDKDESCRIPTION (provided by applicant): The goal of this Type 2 Competitive Renewal SBIR application to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is to conduct a phase I/II clinical trial to investigate the safety and earlyefficacy of a novel antimicrobial living human skin substitute for the treatment of a life-threatening complication of diabetes: chronic, nonhea ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Creating a predictive vascular system for early development
SBC: HemoShear Therapeutics, LLC Topic: NHLBIDESCRIPTION (provided by applicant): The frequent inability of in vitro assays and animal models to accurately predict human response to a new drug candidate results in costly drug development failures. HemoShear has developed a platform technology for biodiscovery and drug pharmacology screening that replicates human biological function in healthy and diseased organ systems by applying human-deri ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Clinical Development of 4-Cl-KYN to Treat Pain
SBC: VISTAGEN THERAPEUTICS, INC. Topic: N/ADESCRIPTION (provided by applicant): we proposed to develop a novel drug, 4-CI-KYN to treat neuropathic pain. 4-CI-KYN is a pro-drug of 7-Chlorokynurenic acid (7-Cl-KYNA), a chlorinated analogue of kynurenic acid, which is a natural neuromodulator and one of the most potent and specific GlyB antagonists known to man, which blocks glutamate transmission through the NMDA receptor. This receptor is i ...
SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health -
Pachyonychia congenita clinical trial using therapeutic self-delivery siRNAs
SBC: TRANSDERM, INC. Topic: NIAMSDESCRIPTION (provided by applicant): RNA interference (RNAi) has the potential to revolutionize treatment of dominant genetic disorders. Small inhibitory RNAs (siRNAs) are highly potent and selective, demonstrating remarkable single-nucleotide specificity.Clinical trials using siRNAs are currently underway for a number of indications including skin. Facilitated by Phase 1 funding, a small one pati ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Knowledge Management System for Multilingual Health Content
SBC: Transcendent International, LLC Topic: N/ADESCRIPTION (provided by applicant): The aim of the proposed project is to develop an advanced, web-based knowledge management system for the creation and distribution of multilingual, patient-oriented documents. The system provides a vast library of pre-translated documents and document templates for medical, educational, and administrative materials used in patient-care. System users will be abl ...
SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health -
Optimization of CXCR1/2 antagonist SX-576 for the treatment of BPD and COPD
SBC: Syntrix Biosystems, Inc. Topic: NHLBIDESCRIPTION (provided by applicant): SX-576 is a small molecule CXCR1/2 antagonist that potently blocks the migration of neutrophils to sites of injury and/or inflammation. SX-576 is being developed as a potential therapeutic for the treatment of pulmonaryinflammatory diseases, such as bronchopulmonary dysplasia (BPD) and chronic obstructive pulmonary disease (COPD). In this study, the pharmacokin ...
SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
Induction of Donor Tolerance in Renal Transplants
SBC: REGENEREX, LLC Topic: NIDDKDESCRIPTION: Renal transplantation is the preferred therapeutic approach for end organ failure. However, the chronic use of immunosuppressive agents is critical to prevent rejection. The drugs are costly ( 15,000-25,000/year) and have significant toxicities including opportunistic infection, an increased rate of malignancy, nephrotoxicity, and other end organ damage. The induction of donor-specifi ...
STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health -
New Cancer Vaccine Technology Based on DRibbles Produced by Tumor Cells
SBC: UBIVAC, LLC Topic: N/ADESCRIPTION (provided by applicant): Recent advances in cellular immunology have revolutionized our understanding of antigen processing and presentation. UBIVAC, LLC, has an exclusive option on technology (patent pending) that exploits these developments that was developed by Dr. Hong-Ming Hu. Further, the founders of UBIVAC (Drs. Hu and Fox) and their collaborators have investigated additional tr ...
SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health -
Arterial-Mimetic Grafts Molded from Purified Proteins
SBC: Gel-Del Technologies, Inc. Topic: N/ADESCRIPTION (provided by applicant): Peripheral artery disease and trauma are leading causes of morbidity and amputation in the United States. Recent advances in biomaterials provide for potential development of small diameter vascular grafts as a life-saving treatment. Development of a life-long graft (lt 6 mm id) requires a construct that will not cause significant blood clotting/thrombosis and ...
SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health